Don't Rush to Recommend Olumiant or Xeljanz XR for Rheumatoid Arthritis

December 2018

Olumiant (baricitinib) and Xeljanz XR (tofacitinib) will be new once-daily oral meds for rheumatoid arthritis (RA).

Olumiant (oh-LOO-mee-ant) is the second Janus kinase (JAK) inhibitor for RA on the market after Xeljanz.

And now once-daily Xeljanz XR may simplify dosing over Xeljanz BID.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Antithrombotics Don't Suggest Xarelto for Most Coronary or Peripheral Artery Disease Patients
Raynaud's Know Which Meds Worsen or Improve Raynaud's Phenomenon
Aspirin Don't Recommend Aspirin to Prevent Cancer
Compounding Be Ready for New Non-Sterile Compounding Practice Requirements
Supplements Be Ready for Questions About the Activated Charcoal "Health" Trend
Biosimilars Address Confusion About Biosimilars
Women's Health Watch for Orilissa, a New Med for Endometriosis
Rheumatoid Arthritis Don't Rush to Recommend Olumiant or Xeljanz XR for Rheumatoid Arthritis
Depression Weigh Antidepressant Options for Older Patients
Hyponatremia Stay Alert for Meds That May Lead to Low Sodium Levels
Pediatrics Prepare for Questions About Treating Croup
Med Safety Extinguish Issues With Meds That Can Catch Fire